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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting approximately 2% of  the popu-
lation, and is characterized by rapid and irregular impulse initiation and propagation throughout the atrial 
myocardium, predisposing to increased risk of  stroke, heart failure (HF), and death (1, 2). As many as 50% 
of  patients with severe HF also have AF (3–5), which is not surprising given the number of  shared risk fac-
tors, including hypertension, obesity, diabetes, and coronary artery disease, underlying the pathophysiolo-
gy of  both HF and AF (6). AF is classified as paroxysmal if  sinus rhythm returns spontaneously or follow-
ing intervention within 7 days, persistent if  it lasts greater than 7 days, and long-standing persistent when 
AF lasts longer than 1 year and is refractory to treatment (7). While HF patients with concomitant AF 
have higher rates of  hospitalization and death (8, 9), current pharmacologic and catheter-based therapies 
aimed at maintaining normal sinus rhythm remain limited in efficacy. Even for paroxysmal AF, which is 
the most responsive to treatment, recurrence rates range between 40% and 60% within 1 year after ablation 
therapy (10, 11). The longer the AF duration, the more likely it is to be resistant to treatment, prompting 
the dogma “AF begets AF” (12, 13). Despite the high and rising health care burden for AF, the molecular 
mechanism(s) underlying AF pathogenesis remain largely unknown (2, 14). AF most often results from 
combined effects of  age, genetics, and acquired risk factors. Thus, a more in-depth molecular understand-
ing of  disease pathogenesis may enable recognition of  patient-specific factors and development of  precision 
medicine–based therapies targeting underlying mechanisms.
AF cellular mechanisms include an initiating trigger, related to Ca2+-mediated early afterdepolariza-
tions or delayed afterdepolarizations, combined with a vulnerable substrate myocardium (13, 15). Trigger 
foci often originate from the pulmonary veins, and in the setting of  a vulnerable substrate, reentrant circuits 
are maintained within the posterior left atrium (LA) (16). A vulnerable substrate can include a variety of  
cardiovascular pathologies, such as atrial chamber dilation, fibrosis, conduction velocity (CV) slowing, or 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, yet the molecular signature of the 
vulnerable atrial substrate is not well understood. Here, we delineated a distinct transcriptional 
signature in right versus left atrial cardiomyocytes (CMs) at baseline and identified chamber-
specific gene expression changes in patients with a history of AF in the setting of end-stage heart 
failure (AF+HF) that are not present in heart failure alone (HF). We observed that human left atrial 
(LA) CMs exhibited Notch pathway activation and increased ploidy in AF+HF but not in HF alone. 
Transient activation of Notch signaling within adult CMs in a murine genetic model is sufficient to 
increase ploidy in both atrial chambers. Notch activation within LA CMs generated a transcriptomic 
fingerprint resembling AF, with dysregulation of transcription factor and ion channel genes, 
including Pitx2, Tbx5, Kcnh2, Kcnq1, and Kcnip2. Notch activation also produced distinct cellular 
electrophysiologic responses in LA versus right atrial CMs, prolonging the action potential duration 
(APD) without altering the upstroke velocity in the left atrium and reducing the maximal upstroke 
velocity without altering the APD in the right atrium. Our results support a shared human/murine 
model of increased Notch pathway activity predisposing to AF.
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changes in the effective refractory period (ERP) due to underlying ion channel remodeling (17–19). Though 
the most common acquired forms of  AF are not Mendelian in inheritance, powerful genome-wide associ-
ation studies (GWAS) have identified associations between genetic variation at more than 100 loci and AF 
(15, 20–24). Single nucleotide polymorphisms in the regulatory regions cause expression variation in local 
cardiac ion channel genes implicated in AF trigger and substrate, providing a molecular model for AF risk 
associations (25, 26). Interestingly, GWAS also identified variation in regulatory regions near cardiac tran-
scription factors (TFs) and modulators of  signaling pathways. The susceptibility locus with the strongest 
association is located in regulatory elements near paired like homeodomain 2 (PITX2), which encodes a TF 
involved in both left-right asymmetry and ion channel gene expression within the LA (24). Pitx2-haploin-
sufficient mice are predisposed to atrial arrhythmias, including atrial flutter and atrial tachycardia, validat-
ing PITX2 as an AF risk locus (27). GWAS loci have also been identified in regions near many other TFs, 
including T-box transcription factor 5 (TBX5). Adult-specific Tbx5 loss-of-function mice have spontaneous 
AF mediated through a Tbx5/Pitx2 gene regulatory network involving membrane effector genes, such as 
sodium voltage-gated channel alpha subunit 5 (Scn5a, which encodes the main voltage-gated sodium chan-
nel in the heart, Nav1.5), gap junction protein alpha (which encodes connexin 43), and calcium handling 
genes (28). Therefore, elucidating the gene regulatory networks that maintain atrial rhythm and are altered 
by genetic perturbation or cardiac insult will be central to understanding AF risk.
Transcriptomic analysis of  human atrial tissue will be an important tool for understanding the under-
lying AF mechanisms. Previous studies aimed at understanding the right versus left atrial transcriptome in 
nonfailing (NF) hearts, HF, or AF have often focused on the LA appendage (LAA) or right atrial append-
age primarily because of  tissue availability (29–31), while the LA posterior wall (LAPW) is a key anchor 
point for atrial reentrant activity (32–34). In addition, previous analyses of  bulk tissue are complicated by 
changes in cellular composition of  the LA in AF, including increased fibrosis. To overcome these limita-
tions and better understand the transcriptional changes specifically in cardiomyocytes (CMs) underlying 
the vulnerable electrical substrate, we isolated and sequenced human right atrium (RA) and LA CM nuclei 
(CMN) from patients with a history of  AF with end-stage heart failure (AF+HF) and with a history of  
end-stage HF alone (HF). The RA and LA had a largely distinct transcriptional signature in AF+HF when 
compared with either NF or HF alone, and among many dysregulated genes, we found the direct Notch 
target hairy and enhancer of  split-1 (HES1) was significantly upregulated in human LA CMN. In compari-
son, HES1 was not upregulated in AF+HF RA CMN or in HF CMN of  either atrial chamber.
Here, we observed an association between Notch pathway activation, increased CM ploidy, and AF 
prevalence. Notch signaling is a strong mitogenic stimulus in developing CMs (35). Shortly after birth, 
mammalian CMs lose the ability to undergo cytokinesis in response to mitogenic stimuli during cardiac 
injury or stress but retain the ability to undergo DNA endoreplication (36, 37). As a result, in adult humans 
CMN transition from a primarily diploid (2n) population to a mixture containing tetraploid (4n) and even 
higher ploidy (>4n). Very little is understood about the polyploidization process and whether it is protective 
or maladaptive. While myocardial ischemia and congestive HF have been associated with increased CM 
ploidy in human ventricular CMs (36–38), it has not been previously demonstrated whether atrial CMs 
undergo similar changes in the setting of  stressors such as AF.
Here, we demonstrate that only LA CMN, and not RA CMN, exhibited increased ploidy in the setting of  
AF+HF, correlating with the chamber-specific Notch activation. Transient Notch signaling activation in adult 
murine CMs using genetic models predisposed to reentrant atrial arrhythmias and increased ploidy in murine 
CMN. Interestingly, Notch activation resulted in distinct transcriptional and electrophysiologic responses in 
the murine RA when compared with the LA. Specifically, Notch activation in the RA resulted in sodium 
channel dysregulation and decreased cellular excitability (39). In contrast, genes encoding several potassium 
channels associated with AF in humans were dysregulated in the Notch-activated LA, giving rise to changes 
in the action potential duration (APD). Taken together, these data identify gene regulatory networks in human 
and murine atria that modulate the vulnerable substrate underlying AF and may guide therapeutic strategies.
Results
Chamber-specific transcriptomic differences in human cardiomyocyte nuclei in AF. The murine LAPW has a differ-
ent embryologic origin than the LAA (40), and LAPW action potentials (APs) are 40% longer when com-
pared with the LAA APs (41), suggesting there is regional heterogeneity within the atria. Previous studies 
have assessed gene expression in the atrial appendages in the setting of  AF (42, 43). To better understand 
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the transcriptional changes accompanying AF that may give rise to the “vulnerable substrate,” we directly 
assessed changes in the LAPW, an anchor point for reentry, as well as within the RA. Given the diversity 
of  cell types within atrial tissue and the increased fibrosis that is associated with disease states such as AF, 
we optimized previously described protocols to isolate CMN (44–46). We performed fluorescent activated 
nuclear sorting (FANS) for pericentriolar material 1 (PCM1), a protein expressed in the nuclear lamina of  
CMs (46), resulting in a highly pure population of  CMN with minimal non-CMN contamination (Sup-
plemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.135319DS1). We initially performed RNA-sequencing on a small set of  NF human ventricular (n = 
1 right ventricle [RV], n = 2 left ventricle [LV]) and atrial (n = 2 RA, n = 1 LA) samples to validate expected 
gene expression differences. Atrial markers natriuretic peptide A and sarcolipin were enriched in both the 
RA and LA, while the ventricular marker myosin light chain 2 was enriched in the RV and LV, as expected. 
The sequencing depth was sufficient to resolve TFs expressed at low levels in adult hearts, as evidenced by 
enrichment of  PITX2 in the LA (Supplemental Table 1).
We investigated global transcriptional differences in human CMN between patients with a history of  
AF+HF or HF and those without a clinical history of  AF or HF (NF). To accomplish this, we performed 
RNA-sequencing on CMN isolated from right and left atrial tissue of  hearts rejected for transplantation with-
out a history of  HF (NF controls, n = 3–7; Supplemental Table 2), CMN from explanted hearts from patients 
with end-stage HF undergoing heart transplantation (HF, n = 3, Supplemental Table 3), and CMN from 
patients with end-stage HF who underwent a heart transplant with a documented history of  AF on at least 1 
ECG (AF+HF, n = 5; Supplemental Table 3). Principal components analysis (PCA) to ascertain the variation 
within our RNA-sequencing data sets demonstrated that samples from each of  the 6 groups (NF RA, NF LA, 
HF RA, HF LA, AF+HF RA, AF+HF LA) clustered together, with AF+HF versus HF versus NF variance 
mostly comprising the first component and right versus left atria mostly comprising the second component 
(Figure 1A). A total of  412 transcripts were dysregulated in RA CMN of HF versus NF samples (192 up and 
220 down), while 628 transcripts were dysregulated (266 up and 362 down) in the LA CMN of HF versus 
NF samples using a linear fold change no more than 0.667 or at least 1.5 and a false discovery rate (FDR) less 
than 0.05, respectively (Figure 1B). Using identical analysis parameters, substantially more transcripts (4360 
total, 1312 up and 3048 down) were dysregulated in RA CMN of AF+HF versus NF samples, while 1887 
transcripts (572 up and 1315 down) were dysregulated in the LA CMN of AF+HF versus NF samples (Figure 
1C). Similarly, there was a low frequency of  overlap of  transcripts dysregulated in HF alone with those dys-
regulated in AF+HF. Specifically, of  the transcripts dysregulated in AF+HF, approximately 2% (92 of  4360 
transcripts in the AF+HF RA) and approximately 11% (200 of  1887 transcripts in the AF+HF LA) were also 
changed in HF alone. These data suggest that unique transcriptional changes occur with AF in right versus 
left atria and that greater than 89% of the differentially expressed transcript differences in AF+HF atria are 
specific to AF and not secondary to HF alone (Figure 1, A–C, and Supplemental Tables 4–8).
Among the many differentially regulated genes in AF+HF LA were subunits encoding ion channels or 
their interacting proteins, such as potassium voltage-gated channel interacting protein 2 (KCNIP2), potassi-
um calcium-activated channel subfamily N member 2, and calcium voltage-gated channel subunit alpha1 D 
(Supplemental Tables 4, 5, 8, and 9), which were expected based on previous studies associating these ion 
channels with AF (20, 47, 48). One of  the downregulated transcripts in AF+HF LA samples was PITX2, 
which encodes a TF involved in left-right asymmetry. Therefore, we asked whether AF gene expression 
changes occur predominantly in transcripts differentially expressed between the LA and RA at baseline. 
There were 1180 differentially expressed transcripts between NF LA versus NF RA at baseline (614 up and 
566 down). When comparing AF+HF against NF counterparts, approximately 2% differentially expressed 
transcripts changed within AF+HF RA (99 of  4360), and approximately 2% (39 of  1887) in AF+HF LA 
(Supplemental Table 8). Therefore, dysregulated transcripts in AF do not predominantly represent an over-
all change in left versus right chamber identity.
More than 100 loci have been associated with AF through GWAS (22). While GWAS offers pow-
erful and unbiased genome-wide information, it is not able to provide cell type specificity or specific 
gene expression changes, which may be caused by the risk variants. To probe this relationship further, 
we generated a heatmap of  genes located near AF GWAS loci and interrogated whether transcriptional 
changes occurred within CMs in our data set. A total of  18 GWAS-associated transcripts were dysregu-
lated in RA CMN of  AF+HF versus NF samples (10 up and 8 down) using a linear fold change no more 
than 0.667 or at least 1.5 and FDR less than 0.05, while none of  these changes were observed in HF 
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alone (Supplemental Figure 2 and Supplemental Table 9). Similarly, 19 transcripts were dysregulated 
(6 up and 13 down) in the LA CMN of  AF+HF versus NF samples, and the majority of  these changes 
(63%) also were not seen in HF alone (Supplemental Figure 2 and Supplemental Table 9). This data set 
provides a useful resource to guide future cell type–specific experimentation related to the mechanisms 
underlying AF.
Given the distinct global transcriptomic signatures of  right versus left atrial CMN in AF, we asked 
whether differential regulation of  TFs may underlie the atrial gene regulatory programs. Using a fold change 
threshold of  no more than 0.667 or at least 1.5 and FDR less than 0.05, we observed that the majority of  TFs 
Figure 1. Chamber-specific transcriptomic differences in human atrial fibrillation cardiomyocyte nuclei. RNA-sequencing was performed on isolated 
cardiomyocyte nuclei (CMN) from human right atrium (RA) and left atrium (LA) from nonfailing (NF) donor hearts rejected for transplantation with no 
history of atrial fibrillation (AF), explanted hearts from individuals with end-stage heart failure (HF) who received a heart transplant without a history 
of AF, and end-stage heart failure with a documented history of AF (AF+HF). (A) Principal components analysis (PCA) plot showing the distribution of 
variance among all human samples (NF RA, light teal; AF+HF RA, dark blue; HF RA, light blue; NF LA, brown; AF+HF LA, bright orange; HF LA, orange). 
Venn diagrams representing the number of differentially upregulated (top) and downregulated (bottom) transcripts in the human RA or LA CMN with (B) 
HF or (C) AF+HF when compared with NF controls. (D) Heatmap with color scale showing the relative expression levels (Z score; red, up; blue, down) of 
transcription factors (TFs) differentially expressed in AF+HF RA when compared with NF RA. Relative expression levels of the same TFs are shown for 
each of the other group comparisons, including AH+HF LA compared with NF LA, HF LA compared with NF LA, HF RA compared with NF RA, as well as a 
comparison of NF LA to NF RA. (E) Similar heatmap analysis as shown in D, except the TFs shown are those differentially expressed in AF+HF LA when 
compared with NF LA. RNA-sequencing performed sequentially on 2 batches: batch 1: symbols with black outline on PCA, n = 9 individual RA (n = 6 NF, n 
= 3 HF) and n = 9 individual LA (n = 6 NF, n = 3 HF). Batch 2: symbols without black outline on PCA, n = 8 individual RA (n = 3 NF, n = 5 AF+HF) and n = 10 
individual LA (n = 5 NF, n = 5 AF+HF). Transcripts with a fold change threshold of no more than 0.667 or at least 1.5 and false discovery rate (FDR) less than 
0.05 were considered statistically significant.
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were also dysregulated only within the AF+HF RA (Figure 1D; 140 unique TFs) or AF+HF LA (Figure 
1E; 46 unique TFs), while only 9 TFs (~5% of  total) met these criteria in both atria (Figure 1, D and E; and 
Supplemental Table 10). Several TFs dysregulated within LA CMN have previously been associated with 
predisposition to AF both in humans and in animal models, including PITX2 (fold change = 0.37, FDR = 
2.42E-02) (27, 49) and short stature homeobox protein 2 (SHOX2; fold change = 0.08, FDR = 2.37E-31) 
(50, 51). Additional TFs specifically dysregulated within human LA CMN have been linked with atrial gene 
regulation in murine models, including HOP homeobox (52) (fold change = 3.35, FDR = 8.31E-03) and 
paralogs of  ETS variant 1 (ETV1; ref. 53), including ETV5 (fold change = 2.00, FDR = 1.84E-03) and ETV6 
(fold change = 0.59, FDR = 1.28E-02). Interestingly, several TFs were dysregulated in both HF and AF+HF 
(SHOX2 and ETV6), while the majority of  TFs are unique to AF+HF. These data provide further rationale 
for investigating a chamber-specific role of  TFs in regulating atrial gene networks in the context of  AF.
CM ploidy is increased in atrial CMs in human AF and in Notch-activated mice. The FANS protocol described 
above to sort CMN using PCM1 can resolve distinct ploidy populations based on DAPI intensity (Supple-
mental Figure 3). At baseline, there were no differences in ploidy between the LA and RA in NF hearts, 
with a distribution of  approximately 47% 2n cardiomyocytes, 45% 4n, and 7% >4n at baseline in both atrial 
chambers (Figure 2A). Similarly, in HF alone, the ploidy distribution was similar between the RA and LA 
(Figure 2B). In contrast, in the setting of  AF+HF, there was a relative reduction of  2n nuclei in the LA, with 
concomitant increases in both the 4n and >4n LA CMN populations (Figure 2C). This increase in the >4n 
population remained statistically significant when directly comparing the AF+HF LA with NF LA (13% 
versus 7%, P < 0.001). To our knowledge, this is the first association of  increased CM ploidy with human AF.
To better understand factors that could contribute to increased CM ploidy in AF+HF LA, we used a 
computational tool that integrates machine learning approaches to classify differentially expressed genes 
into biological categories (CompBio, https://www.percayai.com) and found that Notch signaling was dys-
regulated in the LA, but not the RA, in the setting of  AF+HF. Multiple Notch pathway components were 
dysregulated in AF+HF, including upregulation of  the direct Notch target HES1 in the LA (fold change 
= 2.39, FDR = 2.66E-03) but not in the RA (Supplemental Figure 4 and Supplemental Tables 4, 5, and 
10). Additionally, the Notch pathway was not upregulated in atrial CMN with HF alone, as only 1 of  the 
53 genes in the Kyoto Encyclopedia of  Genes and Genomes database changed in either HF atria (Supple-
mental Figure 4 and Supplemental Tables 6 and 7). In the Drosophila gut, Notch signaling has been asso-
ciated with endoreplication (54, 55). Specifically, Delta/Notch signaling induces Hindsight, which inhibits 
cyclin-dependent kinase activity (56). To directly test whether Notch signaling may regulate polyploidiza-
tion within the atria, we used a doxycycline-inducible genetic model to probe the effects of  Notch activation 
within adult myocardium (inducible Notch intracellular domain, iNICD) (39). In both the RA and LA, 
transient Notch activation for 3 weeks was sufficient to significantly increase 4n nuclei (13% up to 17%) 
at the expense of  2n nuclei (85% down to 81%) in mice (Figure 3, A and B; and Supplemental Figure 5), 
suggesting a potential role for Notch signaling in atrial polyploidization in AF.
Notch activation differentially regulates the transcriptome of  the murine left versus right atrium. Previous 
work from our group demonstrated that transient Notch activation in a murine model predisposes to 
reentrant atrial arrhythmias (39). Given the chamber-specific responses in human atria in the setting of  
AF (Figure 1), we compared gene dysregulation in the Notch-activated LA with the RA from the same 
animals (Figure 4). A total of  896 genes were upregulated in response to Notch signaling in either the 
LA or RA, while only approximately 32% (286 genes) were upregulated in both atria (Figure 4A; Sup-
plemental Table 11). Similarly, 562 genes were downregulated in response to Notch signaling, but only 
approximately 29% (161 genes) were downregulated in both the RA and LA (Figure 4A; Supplemental 
Table 11). Using Ingenuity Pathway Analysis software, GO analysis on differentially regulated tran-
scripts in the Notch-activated LA revealed that, of  the top 25 diseases and functions, 14 were related 
to arrhythmias, and 8 pathways were related to atrial arrhythmias (Figure 4B; Supplemental Table 12). 
This transcriptional signature occurred in the absence of  structural changes within the LA (Supplemen-
tal Figure 6). Validation of  the RNA-sequencing for specific AF-associated genes in a second murine 
cohort demonstrated dysregulation of  genes encoding K+ channel subunits comprising Ito (Kcnip2, 0.37 
± 0.11, P < 0.001), IKr (potassium voltage-gated channel subfamily H member 2, Kcnh2, 1.4 ± 0.067, 
P < 0.001), and IKs (potassium voltage-gated channel subfamily Q member 1, Kcnq1, 2.3 ± 0.064, P < 
0.000001) (Figure 4C, Supplemental Table 14). Several TFs associated with AF were also dysregulated 
in the LA after Notch activation, including the direct Notch target Hes1 (5.17 ± 0.053, P < 0.00000001), 
6insight.jci.org   https://doi.org/10.1172/jci.insight.135319
R E S E A R C H  A R T I C L E
Tbx5 (0.79 ± 0.078, P < 0.05), and Pitx2 (1.5 ± 0.11, P < 0.001) (Figure 4D, Supplemental Table 14). 
Although Pitx2 has traditionally been thought to be downregulated in human and murine models of  AF, 
these studies have mostly been associated with bulk tissue sequencing, which is not cell type specific. 
There is also evidence that PITX2C is upregulated specifically in CMs of  humans with chronic AF, and 
models of  human atrial cells suggest that PITX2 upregulation can increase the risk of  chronic AF (57, 
58). These seemingly contradictory results suggest that Pitx2 levels are sensitive to change in the setting 
of  AF and that either up- or downregulation may be associated with an arrhythmic phenotype.
The murine LA AP was prolonged after Notch activation and did not respond to IKr blockade. Given dis-
tinct transcriptomic changes in right and left atria after Notch activation, we asked whether the cel-
lular electrophysiologic response is also distinct. We previously reported that Notch activation within 
the RA leads to persistently reduced Scn5a expression, CV slowing, and reduced dVm/dtmax consistent 
with reduced sodium current, without affecting the resting membrane potential (RMP) or APD (39). 
While Scn5a expression was downregulated in the RA after Notch activation, in contrast, it remained 
unchanged within the LA (Supplemental Table 11). In contrast to findings in the RA, we observed 
LA-specific expression changes in genes encoding subunits of  voltage-gated potassium channels (Fig-
ure 4C). To determine whether these transcriptional changes may result in functional changes in atri-
al electrophysiology, we performed sharp microelectrode recordings on Langendorff-perfused murine 
hearts. Notch signaling was activated for 4 weeks followed by a minimum 4-month washout period to 
determine whether electrophysiologic effects were persistent. To our surprise, we found that the LA 
APD was persistently prolonged during all phases of  repolarization, including APD20, APD50, APD70, 
and APD90, during sinus rhythm (Figure 5, A–E; Supplemental Figure 7; Supplemental Table 13) while 
no other measured parameters, including RMP, dVm/dtmax, AP amplitude, or ERP, were significantly 
changed in the LA (Figure 5, F–I; Supplemental Table 13). Given that APD can vary based on stimulus 
cycle length, we also performed sharp microelectrode recordings during 10 Hz pacing and observed 
consistent APD prolongation during all phases of  repolarization in the Notch-activated LA (Supple-
mental Figure 8; Supplemental Table 13). Therefore, chamber-specific transcriptional responses predict 
cellular electrophysiology and demonstrate that transient Notch activation in atrial CMs can cause 
long-term changes in LA electrophysiology.
In rodent atria, high Ito current densities dominate during all phases of  repolarization and account for 
the remarkably abbreviated APs lacking a clear plateau phase (59). Although mice express many of  the 
genes encoding subunits of  K+ channels found in humans, IKr and IKs currents contribute minimally to repo-
larization in adult murine hearts (60–62). The Notch-activated transcriptional signature and directionality of  
K+ channel subunit gene expression matched those observed in human AF, including upregulation of  Kcnh2 
(subunit of  IKr) and Kcnq1 (subunit of  IKs). However, in contrast to the shorter APD typically observed in 
the human atria during fibrillation (63), Notch activation prolonged the murine LA APD (Figure 5, A–E). 
Downregulation of  Kcnip2, which encodes a subunit of  Ito, is reduced in both our murine model and in 
human AF (64–66). Kcnip2 downregulation may contribute to prolongation throughout all phases of  the AP 
Figure 2. CM ploidy is increased in LA CMs of humans with AF. CMN were isolated from the RA and LA of NF, HF, and AF+HF. Nuclei were sorted based on 
DAPI and PCM1 staining, and distinct ploidy populations (2n, 4n, >4n) were identified based on differences in DAPI intensity (Supplemental Figure 3). (A) 
CMN ploidy in NF RA versus NF LA is similar. (B) CMN ploidy in HF RA versus HF LA is also similar. (C) Comparison of ploidy in AF+HF RA versus AF+HF LA 
shows loss of 2n nuclei, with concomitant increase in 4n and >4n or higher ploidy nuclei in the LA in the setting of AF. Ploidy experiments were performed 
on 2 sample batches: batch 1: (A and C) n = 9 NF RA, n = 9 NF LA, n = 4 AF+HF RA, n = 6 AF+HF LA; batch 2: (B) n = 3 HF RA, n = 3 HF LA. Data are present-
ed as the mean from each group ± SEM. P < 0.05 was considered statistically significant. *P < 0.05; NS, not significant. Unpaired Student’s 2-tailed t test 
with a Welch’s correction was performed for all comparisons.
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observed in Notch-activated mice, while in humans, it may correlate with the prolonged AP duration at 20% 
repolarization observed in AF (67). To demonstrate whether Notch-mediated increases in Kcnh2 expression 
would result in increased IKr and influence atrial APs, we acutely activated Notch signaling for 4 weeks and 
found similar APD changes at baseline (Figure 5J) to those that persisted after a prolonged washout period 
(Figure 5A). Next, we treated Notch-activated mice with dofetilide, the class III antiarrhythmic drug com-
monly used to treat AF through blocking the IKr current (Supplemental Figure 7, Supplemental Table 13) 
(68). Although the APD was prolonged at baseline in the iNICD LA (Figure 5J, Supplemental Table 13), 10 
nM dofetilide did not further prolong the APD20, APD50, APD70, or APD90 or affect RMP, dVm/dtmax, or AP 
amplitude (Figure 5, J–N; Supplemental Figure 7; Supplemental Figure 9; and Supplemental Table 13). Tak-
en together, these data suggest that the murine model recapitulates transcriptional responses seen in humans, 
although differences in individual currents potentially germane to AF risk exist between species.
Discussion
One of  the most striking and consistent findings across species described herein is the observation of  distinct 
transcriptional networks within the RA and LA. AF is a highly complex and heterogeneic disease (69), which 
manifests in the presence of  various clinical backgrounds ranging from classic systolic HF to lone familial 
AF (3, 70). This detailed investigation of  the transcriptome of  human LAPW versus RA CMN determined 
that more genes are differentially regulated than similarly regulated between human atria in the setting of  AF 
(Figure 1, Supplemental Tables 4 and 5). Here, we provide a resource detailing AF-associated GWAS loci and 
TF expression changes specifically within human right versus left atrial CMN, which may be used in guiding 
future cell type–specific experimentation related to AF mechanisms (Supplemental Figure 2, Supplemental 
Tables 9 and 10). Although there was very little overlap between changes observed in the RA and LA CMN, 
both chambers exhibited significant transcriptional changes, which may reflect the involvement of  both the 
RA and LA in AF perpetuation. Although AF is frequently considered an LA disease, these data further sup-
port the emerging notion that the RA could contribute to AF by mechanisms different from those operative in 
the LA. The emerging need for extensive ablation of  RA sites in addition to pulmonary vein isolation and LA 
modification in many patients, particularly those with persistent AF, supports this notion.
Figure 3. CM ploidy is increased in Notch-activated murine atrial CMs. CMN were isolated from the RA and LA in a murine 
genetic model of adult Notch activation (iNICD) and compared with littermate controls. FANS was performed for DAPI and 
PCM1 staining, and distinct ploidy populations (2n, 4n, >4n) were identified based on differences in DAPI intensity (Supple-
mental Figure 5). At baseline, mice have a higher 2n population (85% in the RA and 84% in the LA) when compared with 
human atria. Nuclear ploidy distribution of control versus iNICD PCM1-sorted murine (A) RA CMN and (B) LA CMN.  
n = 6 control RA, n = 6 iNICD RA. Two left atria were pooled for each biological replicate; n = 4 control LA, n = 4 iNICD LA. 
Data are presented as the mean from each group ± SEM. P < 0.05 was considered statistically significant. *P < 0.05;  
NS, not significant. Unpaired Student’s 2-tailed t test with a Welch’s correction was performed for all comparisons.
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The AF GWAS patient population used as a reference (22) shares similar comorbidities to the AF 
samples in this manuscript, including age, hypertension, and diabetes. While the number of  patients with 
HF was not defined for the GWAS, the meta-analysis reviewed approximately 65,000 patients with AF, 
including approximately 6500 with unspecified HF compared with the end-stage HF AF samples used 
in this study. It is possible that inherent differences between patient characteristics in the GWAS data set 
versus our cohort could limit our ability to detect relevant changes. At least 1 patient in the AF+HF group 
in our study was in sinus rhythm at the time of  tissue procurement (paroxysmal AF). Since all AF+HF 
samples clustered together on the PCA and were separated from HF-alone samples, this suggests a distinct 
transcriptional profile may exist in AF-susceptible atria independent of  the fibrillation process itself. Our 
finding is consistent with a previous study in dogs demonstrating that HF plus atrial tachycardia (as would 
occur in a patient with HF who develops AF) produced ionic changes distinct from HF or atrial tachycardia 
alone and distinct from predicted additive effects of  HF and atrial tachycardia (71). Therefore, future stud-
ies focused on elucidating the transcriptome throughout various stages of  AF, as well as in association with 
distinct AF-associated clinical entities, may provide additional valuable information.
Figure 4. Notch activation differentially regulates the transcriptome of the murine left versus right atrium. Notch signaling was activated in adult 
CMs (iNICD) followed by RNA-sequencing of the RA and LA. (A) The number of significantly dysregulated transcripts in iNICD RA (orange) and LA 
(yellow) compared with littermate controls is shown, with Venn diagrams demonstrating primarily distinct transcriptional changes within RA and LA. 
(B) Gene ontology (GO) analysis on iNICD LA indicating the statistically significant Ingenuity Pathway Analysis–generated biological diseases that 
are either general or atrium-specific arrhythmia conditions from the top 25 disease categories and the key differentially expressed genes within the 
category. Red indicates downregulated, blue indicates upregulated, and color intensity is positively related to fold change. n = 6 control RA, n = 6 iNICD 
RA, n = 6 control LA, n = 6 iNICD LA. (C and D) Reverse transcription–quantitative polymerase chain reaction (RT-qPCR) validation of genes associated 
with cardiac electrophysiology and AF was performed on the LA of a second cohort of iNICD mice. K+ channel genes (C) and transcription factors (D) 
from the GO analysis that are associated with AF. n = 6 control LA, n = 6 iNICD LA. All fold changes are relative to Tbp. Data are presented as the mean 
from each group ± SEM. P < 0.05 was considered statistically significant. *P < 0.05; ***P < 0.001; ******P < 0.000001; ********P < 0.00000001; NS, 
not significant. Unpaired Student’s 2-tailed t test with a Welch’s correction was performed for all comparisons.
9insight.jci.org   https://doi.org/10.1172/jci.insight.135319
R E S E A R C H  A R T I C L E
Chamber-specific findings were also supported in our murine model of  Notch activation, where tran-
scriptional changes paralleled distinct electrophysiologic reprogramming between the RA and the LA (Figure 
4 and Figure 5). Previous work from our laboratory demonstrated that Notch signaling regulates ion chan-
nel expression in part through chromatin modification (39, 72). The transcriptional and electrophysiologic 
Figure 5. Notch signaling prolongs the murine LA AP and is not responsive to the IKr blocker dofetilide. Sharp 
microelectrode recordings were performed ex vivo on the LA of intact murine hearts while in sinus rhythm in control 
and iNICD mice after a 4-month washout period (A–I) versus during active Notch activation (J–N). In addition, during 
active Notch activation, recordings were taken at baseline (-Dof) versus after 10 nM dofetilide administration, a class III 
antiarrhythmic drug that blocks IKr (+Dof, J–N). (A) Representative averaged LA APs in control (blue) and iNICD (red).  
(B–E) APDs at 20% (B), 50% (C), 70% (D), and 90% (E) repolarization. AP characteristics, including RMP (F), dVm/dtmax 
(G), max amplitude (H), and ERP (I). n = 9 control mice and n = 10 iNICD mice for B–H. n = 7 control mice and n = 7 iNICD 
mice for I. (J) Representative averaged LA APs in iNICD mice at baseline (blue) and after 10 nm dofetilide administration 
(red) demonstrate no shortening of the AP, suggesting absence of IKr current despite transcriptional upregulation 
of Kcnh2 in iNICD mice. (K–N) APDs at 20% (K), 50% (L), 70% (M), and 90% (N) repolarization are also unchanged 
with dofetilide. n = 7 iNICD mice. Data are presented as the mean from each mouse ± SEM. P < 0.05 was considered 
statistically significant. **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant. Unpaired Student’s 2-tailed t 
test with a Welch’s correction was performed for comparisons in B–I. Paired Student’s 2-tailed t test with a Welch’s 
correction was performed for all comparisons in K–N. 
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changes persist long after transient Notch activation, consistent with a reprogramming process. It is known 
clinically that “AF begets AF.” While atrial fibrosis and atrial dilation are known contributing factors to AF 
perpetuation, it will be interesting to further probe the role of  the epigenome in this process.
A recent study demonstrated that HEY1/HEY2 (Hes related family BHLH transcription factor with 
YRPW motif  1/2) TF binding motifs are abundant in open chromatin located near AF-associated GWAS 
loci in human LA tissue (26). HEY1 and HEY2 are direct targets of  Notch signaling that play important 
roles in heart development (73). Interestingly, although we did not detect HEY1 or HEY2 expression in 
human AF+HF atrial CMN, the Notch downstream target HES1 is upregulated specifically in human 
AF+HF LA but not RA (Supplemental Figure 4, Supplemental Tables 5 and 10). The HES1 consensus 
binding motif  (C A/G CGTG) (74) is very similar to the HEY1/HEY2 motif  (CACGTG) (75). Given 
that Notch activation upregulates Hes1 in the murine LA, creating a transcriptional signature resembling 
AF, including dysregulation of  Pitx2 and Tbx5 (Figure 4, B–D), ongoing and future work will further probe 
these gene regulatory networks driving AF susceptibility and perpetuation.
Human CMN are primarily diploid but become tetraploid and even octoploid in the setting of  heart 
dysfunction, suggesting there may be activation of  regenerative signaling pathways associated with new 
DNA synthesis without subsequent nuclear division (37, 38). Furthermore, there is evidence that failing 
hearts that undergo mechanical unloading through left ventricular assist device placement revert from pri-
marily polyploid to diploid (76). We provide the first evidence to our knowledge that ploidy is increased in 
human atrial CMN in the setting of  AF+HF, specifically in the LA (Figure 2). In addition, we show that 
Notch activation in adult atrial CMs is sufficient to induce polyploidization (Figure 3). The potential bene-
fits of  polyploidization in the heart are not fully understood (77). One potential evolutionary benefit could 
be to enable an increase in the metabolic capacity of  a nonregenerative tissue such as the heart through 
funneling energy into gene duplication and additional protein synthesis without requiring dissolution of  
sarcomeres, which might have devastating effects on an already failing heart. Given that there is presum-
ably an increased nuclear size resulting in a reduction of  the nuclear surface-to-volume ratio of  higher ploi-
dy nuclei, there have been examples of  a lower efficiency of  nuclear import of  specific factors resulting in 
small perturbations in gene expression (78, 79). A recent murine study demonstrated that the gene expres-
sion profiles in mono- versus multinucleated ventricular CMs are similar (80). Interestingly, a rabbit study 
demonstrated that LA mononuclear CMs have a more positive RMP and longer APD90 compared with 
binuclear CMs that may be associated with increased arrhythmogenic activity (81). Limitations in atrial 
tissue availability prohibited a thorough analysis of  the effect of  ploidy on human atrial gene expression in 
AF; however, this could be further explored in future studies.
Targeting individual AF arrhythmia mechanisms may provide a basis for the development of  more effec-
tive therapies. Indeed, computational models taking into account individual fibrosis patterns have been used 
for personalizing ablation in a small number of  patients with persistent AF with improved clinical efficacy 
(82). Also in support of  a targeted approach, flecainide, an Nav1.5 blocker used to treat supraventricular 
tachycardias, is more effective in suppressing atrial arrhythmias in the setting of  reduced Pitx2c mRNA lev-
els in mice (83). Despite the promise of  precision medicine approaches targeting molecular pathways, there 
are several barriers complicating this approach, including multifactorial AF etiologies. While it is typically 
thought that perpetuation of  AF is associated with APD shortening and decreased atrial refractoriness (63, 
67, 84, 85), there is also evidence to suggest that the electrophysiologic substrate predisposing to the onset of  
AF may be varied. An intriguing study involving 1308 people without structural heart disease who underwent 
an electrophysiologic study found that the atrial ERP (AERP) increases with age (86). Follow-up of  these sub-
jects over 12 years demonstrated that a prolonged baseline AERP, at least 280 ms, was predictive of  patients 
at significantly increased risk of  developing AF. In another study, individuals with AF associated with sick 
sinus syndrome also demonstrate AP prolongation (87). Therefore, AF is likely to be associated with diverse 
molecular and physiologic signatures. A limitation to the current study is that it only focused on human AF in 
the setting of  HF, and it is possible that the findings may not be relevant to AF in other contexts.
While the Notch-activated murine model recapitulates transcriptomic changes associated with human 
AF, there are electrophysiological differences between murine and human atria. For example, the repolar-
izing current Ito is present in both mice and humans and predominates repolarization in mice, whereas IKr 
and IKs do not contribute significantly to murine repolarization. Downregulation of  Kcnip2, which encodes 
a subunit of  Ito, is reduced in both our murine model and in human AF (64–66) and may contribute to 
prolongation throughout all phases of  the AP observed in Notch-activated mice. To demonstrate whether 
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Notch-mediated increases in Kcnh2 expression would result in increased IKr and influence atrial APs, we 
treated Notch-activated mice with the IKr blocker dofetilide and saw no change in the APD (Figure 5, J–N; 
and Supplemental Table 13), suggesting that IKr is not present.
Given these differences in ionic currents in human atria when compared with animal models, there is 
a need for improved human model systems to better understand atrial arrhythmia mechanisms and test AF 
therapeutics. While the stem cell field has come a long way toward providing a valuable in vitro platform 
for understanding human biology and enabling high-throughput screening, it remains difficult to approx-
imate the native atrial tissue architecture and adult atrial electrophysiologic properties (88). For example, 
typical conduction velocities in stem cell models are often an order of  magnitude lower than velocities in 
human atria. Additionally, as demonstrated above, important differences exist between the human right 
and left atrium, and it has not been established whether atrial CMs derived from induced pluripotent stem 
cells behave more similarly to right or left atrial CMs. Future work will aim to establish robust platforms 
for elucidating underlying AF mechanisms, which may include human ex vivo models of  atrial conduction 
to aid in the drug development process. A deeper understanding of  the mechanisms underlying AF may 
enable development of  new precision medicine strategies to reduce the high societal burden of  AF.
Methods
Animals. αMHC-rtTA (89), tetO_NICD (90) (iNICD) mice have been described previously and were main-
tained on a mixed genetic background. Mice between the ages of  2 and 9 months were used, including age-
matched littermate control animals for comparison. For experiments involving conditional gene expression, 
induction of  NICD expression was accomplished with doxycycline chow (BioServ 200 mg/kg) during the 
stated time points. Mice of  both sexes were used in all studies, and though experiments were not powered 
to specifically detect sex differences, no obvious differences in any parameters were noted between sexes.
Human tissue acquisition. NF human hearts were obtained from Mid-America Transplant Services (MTS) 
in St. Louis, Missouri, USA. Experimental protocols were approved by the Washington University in St. 
Louis Institutional Review Board (IRB). Informed consent was obtained for all tissue used in this study. 
Tissue samples from the RV, LV, RA free wall, and LAPW of  each heart were collected and immediately 
flash-frozen in liquid nitrogen and stored at −80°C. AF+HF and HF human heart tissues were obtained 
from the Translational Cardiovascular Biobank & Repository (TCBR) at Washington University in St Lou-
is. Due to previously acquired patient demographics during initial tissue procurement, there is a potential 
for underrepresentation of  clinically relevant data. The available patient characteristics of  these donors are 
summarized in Supplemental Tables 2 and 3.
Isolation and sorting of  human and mouse CMN. CMN isolation was modified based on previously pub-
lished studies (44–46). Previously snap-frozen human samples or a combination of  2 mouse left atria were 
first mechanically homogenized (Bio-Gen PRO200, PRO Scientific) on ice in supplemented homogenization 
buffer (SHB). The crude homogenate was transferred to a 40 mL Dounce tissue grinder with glass pestle 
(Kimble) and underwent a minimum of 75 strokes. Progression of  nuclei extraction was crudely assessed 
using a ×10 objective light microscope (Nikon Eclipse E200) after staining a nuclei aliquot with trypan blue. 
Samples were strained using a 40 μm nylon cell strainer (Corning) and centrifuged at 1000g (Avanti J-E Cen-
trifuge, Beckman Coulter) for 5 minutes at 4°C. Supernatant was discarded, pellet was resuspended in SHB, 
and nuclei were stained with anti-PCM1 (1:1000, HPA023370, MilliporeSigma) for 30 minutes on a Nutator 
(Thermo Fisher Scientific) at 4°C. To wash nuclei, samples were centrifuged at 1000g (Centrifuge 5430R, 
Eppendorf) for 5 minutes at 4°C, supernatant was discarded, and pellet was resuspended in SHB. Samples 
were then stained with corresponding secondary antibody Alexa Fluor 647 (goat anti-rabbit, 1:1000, A21244, 
Invitrogen, Thermo Fisher Scientific) and DAPI (1:45,000, MilliporeSigma) for 20 minutes on a Nutator at 
4°C. Nuclei were washed in SHB, then filtered using 30 μm CellTrics strainer (04-004-2326, Sysmex).
Human and mouse CMN were analyzed and sorted by FANS using a MoFlo sorter (Beckman Coulter) 
with a 100 μm nozzle for batch 1 or Sony SY3200 cell sorter (Sony Biotechnology) with a 100 μm nozzle 
for batch 2 as defined in Figure 1 and Figure 2 in collaboration with the Siteman Flow Cytometry Core 
at Washington University in St. Louis. For all experiments, the initial gate identified nuclei of  interest 
and removed debris (SSC versus FSC), followed by doublet exclusion (SSC-w versus FSC), followed by 
autofluorescence debris exclusion (phycoerythrin versus GFP), followed by identification of  CMN (DAPI 
versus PCM1) and final gate to identify the 2n, 4n, and >4n CMN populations. See Supplemental Figure 3 
and Supplemental Figure 5 for the representative gating strategy of  human and mouse CMN, respectively.
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Histology and immunohistochemistry. Immunohistochemistry was performed on paraffin-embedded sec-
tions. Gross heart morphology and collagen content were examined using Masson’s trichrome stain (Amer-
ican MasterTech Scientific). Wheat germ agglutinin staining was used to visualize cell membranes and 
enable quantification of  CM cell size.
Microelectrode recordings. Investigators were blinded to the sample group allocation during the experi-
ment and analysis of  experimental outcome. Mouse hearts were Langendorff  perfused and were recorded 
while in sinus rhythm and when stimulated at 10 Hz (approximately 600 beats per minute). Using glass 
sharp microelectrodes, single LA CMs were sampled near the epicardial surface. To decrease noise from 
motion artifacts, blebbistatin (0.2 mg/mL) was used to arrest motion and allow for stable microelectrode 
recording without requiring the use of  floating electrodes.
Additional information. All methods related to mouse RT-qPCR (Supplemental Table 14) and 
RNA-sequencing and analysis are detailed in the Supplemental Methods. Expanded methods for 
human tissue acquisition, CMN isolation, histology and immunohistochemistry, and microelectrode 
recordings are also supplied in the Supplemental Methods.
RA RNA-sequencing accession number. RA RNA-sequencing data discussed in this manuscript have been 
deposited in the National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus 
(GEO) database and are accessible through GSE100244.
LA RNA-sequencing accession number. LA RNA-sequencing data discussed in this manuscript have been 
deposited in NCBI’s GEO and are accessible through GSE138253.
Human RNA-sequencing accession number. Data have been deposited in NCBI’s GEO and are accessible 
through GSE138252.
Statistics. All data are expressed as mean ± SEM. Statistical analyses were performed after assessing 
for normal distribution using either paired or unpaired Student’s 2-tailed t tests for comparison of  2 groups 
with a Welch’s correction. Values of  P < 0.05 were considered statistically significant.
Study approval. Animal protocols were approved by the Animal Studies Committee at Washington Univer-
sity in St. Louis, and animals were handled in accordance with the NIH’s Guide for the Care and Use of  Laboratory 
Animals (National Academies Press, 2011). Protocols involving human tissue acquisition were approved by the 
Washington University in St. Louis IRB. Informed consent was obtained for all tissue before inclusion in this 
study. Methods described in this manuscript were performed in accordance with all human research guidelines.
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